Mounting evidence suggests that SGLT2 inhibition may inhibit the growth of SGLT2-expressing carcinomas, including breast cancer [12], cervical cancer [13], hepatocellular cancer [14], prostate cancer, and lung cancer [15]. The gene discussed is SLC5A2; the disease is carcinoma.